Country Club Bank Boosts Holdings in Novo Nordisk A/S $NVO

Country Club Bank boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 83.0% in the third quarter, HoldingsChannel.com reports. The fund owned 49,360 shares of the company’s stock after buying an additional 22,394 shares during the quarter. Country Club Bank’s holdings in Novo Nordisk A/S were worth $2,739,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. NewSquare Capital LLC raised its position in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S during the second quarter worth $37,000. State of Wyoming purchased a new position in Novo Nordisk A/S during the first quarter worth $38,000. Maseco LLP acquired a new position in shares of Novo Nordisk A/S in the second quarter worth $39,000. Finally, Copeland Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 47.3% in the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after acquiring an additional 186 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Jefferies Financial Group began coverage on shares of Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating for the company. Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. HSBC reissued a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have given a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $53.33.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $47.77 on Thursday. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $109.04. The firm has a 50 day moving average price of $50.23 and a 200 day moving average price of $57.93. The company has a market cap of $213.28 billion, a price-to-earnings ratio of 13.89 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.